We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





FDA Authorizes First Nanopore Sequencing-Based Test for SARS-CoV-2

By LabMedica International staff writers
Posted on 25 Sep 2020
Print article
Illustration
Illustration
The US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to the Clear Dx SARS-CoV-2 novel descriptive diagnostic from Clear Labs (San Carlos, CA, USA), making it the first nanopore sequencing-based test for SARS-CoV-2 to receive EUA.

Clear Dx offers a fully automated, nanopore-based NGS solution for simultaneous high-volume diagnosis of SARS-CoV-2 and deeper genomic characterization of the virus. At a price comparable to qPCR, Clear Dx simultaneously improves test accuracy while providing end-to-end results in hours, instead of days. The sequencing analysis enables monitoring for mutations that may confer drug resistance, enhance virulence, and cause loss of diagnostic targets for PCR. Data from the platform will also help advance emerging pharmaceutical interventions which are intended to target COVID-19.

Clear Labs’ proprietary NGS platform leverages the latest technology in automation, molecular testing, machine learning and a proprietary bioinformatics pipeline. Visualized with intuitive software reporting and data analysis, the flexible architecture has allowed the company to quickly develop a turn-key genomics assay to provide more accurate COVID-19 testing. Based on technology which has revolutionized the food safety testing market, the company’s novel descriptive diagnostic addresses current testing limitations, including high false negative rates and binary results that cannot differentiate RNA viruses and subtypes.

“We’re encouraged by the rapid response of the testing market to stop the global spread of COVID-19, and knew that our technology is serving an unmet need,” said Sasan Amini, CEO of Clear Labs. “The powerful combination of our genomics-based assay and bioinformatics software means that laboratories, hospitals and pharmaceutical companies have access to accurate, up-to-date molecular data that will help them better understand and therefore combat the virus.”

Related Links:
Clear Labs

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.